Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Accured Expenses (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Change in Accured Expenses data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 48.26% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $5.2 million, up 44.26%, while the annual FY2025 figure was $5.2 million, 44.26% up from the prior year.
  • Change in Accured Expenses reached $2.2 million in Q4 2025 per OCUL's latest filing, down from $5.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.9 million in Q2 2024 and bottomed at -$14.0 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $751000.0, with a median of $2.0 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: soared 930.32% in 2022, then tumbled 433.9% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $188000.0 in 2021, then skyrocketed by 930.32% to $1.9 million in 2022, then crashed by 164.33% to -$1.2 million in 2023, then skyrocketed by 437.56% to $4.2 million in 2024, then plummeted by 48.26% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.2 million in Q4 2025, $5.4 million in Q3 2025, and $2.8 million in Q2 2025.